Madison Vaccines

12 articles about Madison Vaccines

• Madison Vaccines Incorporated Appoints Jeff Bailey to Its Board of Directors

  10/26/2017

  Madison Vaccines today announced the appointment of Jeff Bailey to the Company’s Board of Directors.

• Madison Vaccines Announces First Patient Dosed In An Expanded Combination Trial Of MVI-816 Plus Keytruda® For Metastatic, Treatment-Resistant Prostate Cancer

  8/2/2017

• Madison Vaccines Expands Clinical Trial Of MVI-118 For Prostate Cancer To University of Washington

  3/21/2017

• Madison Vaccines Says Promising Early Data On The Combination Of Its Lead Prostate Cancer Vaccine With A PD-1 Inhibitor Will Be Presented At Major Medical Meeting Nov. 11th

  11/8/2016

• Madison Vaccines Says Its Investigational New Prostate Cancer Treatment Is Available For The First Time In New Jersey Through A Clinical Trial At Rutgers Cancer Institute Of New Jersey

  10/27/2016

• Madison Vaccines Announces Patient Dosing Underway In Clinical Trial Pairing Its Lead Prostate Cancer Vaccine, MVI-816, With PD1 Inhibitor Pembrolizumab

  8/19/2015

• Madison Vaccines To Present At The 2015 World Vaccine Congress In Washington, D.C., On April 9th

  4/7/2015

• Madison Vaccines Announces Program Expansions For Its Investigational Prostate Cancer Vaccines

  3/10/2015

• Madison Vaccines To Be Used In Clinical Trial Of A New Combination Approach To Immunotherapy Funded By The Prostate Cancer Foundation And The Movember Foundation

  8/28/2014

• Madison Vaccines Announces Expansion Of A Phase 2 Clinical Trial For MVI-816, Its Lead DNA Vaccine For Prostate Cancer

  6/23/2014

• Madison Vaccines Announces The Appointment Of Michael Richman To Its Board Of Directors

  5/14/2014

• Madison Vaccines Closes $8 Million Series A Financing

  1/13/2014